Cassis Polyphenols for Menopause: What a Null Trial Found

Blackcurrant-derived cassis polyphenols have a tidy sales pitch for menopause: improve microcirculation and vasorelaxation, and perhaps hot flashes ease. The first placebo-controlled clinical test did not support it. After four weeks, women taking 400 mg per day of cassis polyphenol had no significant advantage over placebo for hot flashes, sweating, anxiety, sleep, well-being, or quality of life.

The result does not prove that cassis has zero effect. With only 59 participants, the trial could easily miss a small benefit. It does show that this dose did not produce the sort of obvious, near-term symptom relief that would justify treating cassis as an evidence-based menopause intervention.

A well-designed trial, with a consistently null result

In a 2024 randomized, double-blind, placebo-controlled trial by Ohtsuka et al., 59 healthy Japanese women in the climacteric period took either cassis polyphenol tablets providing 400 mg daily or matching placebo tablets for four weeks. Their mean age was 51.3 years and mean body-mass index was 20.8 kg/m². The investigators then followed participants during a two-week post-intervention observation period.

The primary question was practical: did cassis reduce hot flashes? During the four-week intervention, the answer was no. The groups did not differ significantly in hot-flash frequency or hot-flash score. They also did not differ significantly in sweating frequency, the modified Kupperman Index for menopausal symptoms, WHO-5 well-being, WHOQOL-26 quality of life, state or trait anxiety on the STAI, or sleep-quality scores.

That breadth matters. Menopausal symptoms are subjective and responsive to expectation, so blinding and a placebo group are especially useful. The researchers also reported the unfavorable results rather than selecting one flattering measure and leaving the rest in a drawer. A null result across several symptom domains carries more weight than one isolated negative endpoint.

The delayed signal is exploratory, not a delayed cure

During the two-week observation period after supplementation ended, the cassis group had nominally lower hot-flash scores and less sweating than the placebo group. That finding deserves reporting, but not promotion. It was post-hoc, emerged after null results during treatment, and came amid many outcomes measured across several time points.

Those conditions raise the chance of a false-positive result from multiple comparisons. A later difference can occur by chance even when the intervention does nothing. It would become interesting only if a new trial specified delayed effects in advance and reproduced them. For now, it cannot support a claim that cassis needs time to "kick in."

The biological rationale targets a downstream event

Hot flashes begin in the brain's temperature-control circuitry. Estrogen withdrawal alters signaling in hypothalamic KNDy neurons—neurons involving kisspeptin, neurokinin B, and dynorphin—and narrows the thermoneutral zone. Small changes in core temperature can then trigger a heat-dissipation response: flushing, sweating, and a pounding sense that someone has quietly turned up the thermostat.

Cassis anthocyanins were proposed to help through microcirculation and peripheral vasorelaxation. Even if those vascular effects occur in people at this dose, they would address heat dissipation after a hot flash has been triggered, not the central signal that triggers it. That does not make the hypothesis impossible; biology enjoys exceptions. It does mean the rationale is less direct than treatments aimed at neurokinin signaling.

Clinical drug data support that distinction. In the large phase 3 SKYLIGHT 1 trial of fezolinetant, an NK3 receptor antagonist, women with moderate-to-severe vasomotor symptoms had greater reductions in hot-flash frequency and severity than those receiving placebo. A 2025 systematic review and meta-analysis likewise found efficacy for fezolinetant and elinzanetant, which targets NK1 and NK3 receptors. These prescription drugs do not prove that peripheral vascular interventions cannot help, but they strengthen the case that central thermoregulation is the more productive target.

Other nonhormonal approaches have stronger, though uneven, evidence

Botanicals are not interchangeable simply because they contain polyphenols. Soy isoflavones have a more relevant pharmacologic rationale: genistein and daidzein have estrogenic activity, including ERβ agonism. A 2024 systematic review and meta-analysis of randomized trials and a 2025 meta-analysis in perimenopausal women found modest but statistically significant reductions in menopausal symptoms, including hot flashes, across pooled studies. The effects are modest, and the evidence required pooled data from many participants; that is a different evidence position from one 59-person cassis trial.

Yoga also has support beyond a single study. A 2024 systematic review and meta-analysis of randomized trials found improvements in menopausal symptom burden, psychological outcomes, and vasomotor symptom severity. The intervention is not a replacement for medical care when symptoms are severe, but it is a reasonable option with broader potential benefits than a capsule promising better blood flow.

Several other strategies remain preliminary. A meta-analysis of Salvia officinalis reported benefit for hot flashes, although the evidence base is smaller. An exploratory dietary trial found fewer postmenopausal hot flashes with a low-fat plant-based diet, and a related post-hoc analysis linked lower dietary advanced glycation end-product intake with lower hot-flash frequency and severity. Those findings merit follow-up, not certainty.

Probiotics are another developing area. A 2025 systematic review and meta-analysis included 39 studies and 3,187 women and reported improvements in menopausal symptom outcomes in its placebo-controlled meta-analysis. The proposed estrobolome mechanism—gut microbes influencing estrogen metabolism—is plausible, but the studies vary enough that probiotics should not yet be treated as a standardized hot-flash therapy.

What the cassis trial can and cannot tell us

The trial was too small to rule out a modest effect. Roughly 30 women per group provides limited statistical power, especially when symptoms vary from day to day. Four weeks may also be too short for an intervention with a delayed biological effect, and the study did not provide pharmacokinetic data showing whether its anthocyanins reached concentrations likely to affect relevant tissues.

Its participants were healthy Japanese women with a relatively low mean BMI, and their baseline vasomotor symptom severity may not match that of women seeking treatment in a menopause clinic. Lower symptom burden leaves less room for improvement. These limits argue against calling cassis definitively ineffective.

They do not create evidence of benefit. The responsible conclusion is narrower: cassis polyphenol at 400 mg daily did not significantly improve menopausal symptoms over four weeks in this small trial. Until a larger study enrolls women with moderate-to-severe symptoms, follows them for at least 12 weeks, confirms anthocyanin exposure, and defines one primary vasomotor endpoint in advance, cassis remains an unproven supplement for hot flashes.

For menopause hot flashes, cassis has a plausible story about circulation but no affirmative clinical result. Spend your attention on options with replicated evidence, and discuss persistent or disruptive symptoms with a clinician.